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Human pregnancy is accompanied by a mild systemic inflammatory response, which
includes the activation of monocytes circulating in maternal blood.This response is exagger-
ated in preeclampsia, a placental-dependent disorder specific to human pregnancies. We
and others showed that placental syncytiotrophoblast membrane microparticles (STBM)
generated in vitro from normal placentas stimulated peripheral blood monocytes, which
suggest a contribution of STBM to the systemic maternal inflammation. Here, we analyzed
the inflammatory potential of STBM prepared from preeclamptic placentas on primary
monocytes and investigated the mode of action in vitro. STBM generated in vitro by pla-
cental villous explants of normal or preeclamptic placentas were co-incubated with human
peripheral blood monocytes. In some cases, inhibitors of specific cellular functions or sig-
naling pathways were used.The analysis of the monocytic response was performed by flow
cytometry, enzyme-linked immunoassays, real-time PCR, and fluorescence microscopy.
STBM derived from preeclamptic placentas up-regulated the cell surface expression of
CD54, and stimulated the secretion of the pro-inflammatory interleukin (IL)-6 and IL-8 in
a similar, dose-dependent manner as did STBM prepared from normal placentas. STBM
bound to the cell surface of monocytes, but phagocytosis was not necessary for activa-
tion. STBM-induced cytokine secretion was impaired in the presence of inhibitors of toll-like
receptor (TLR) signaling or when nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) activation was blocked. Our results suggest that the inflammatory reaction
in monocytes may be initiated by the interaction of STBM with TLRs, which in turn signal
through NF-κB to mediate the transcription of genes coding for pro-inflammatory factors.
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INTRODUCTION
Preeclampsia is a multi-symptom disorder of the second half of
pregnancy, which affects 2–7% of pregnant women worldwide
(1). Despite extensive research, the etiology of this pathologic
pregnancy condition remains unclear. The current research sug-
gests that, in patients destined to develop preeclampsia, pregnancy
is associated with an increased maternal inflammatory reaction,
which will lead to placental stress and ultimately result in the
mother’s systemic endothelial dysfunction and the large array of
life-threatening symptoms, which characterize the disorder (2–
4). Interestingly, normal pregnancy also induces a physiologic
Abbreviations: 6AQ, 6-amino-4-(4-phenoxyphenylethylamino)quinazoline;
MACS, magnetic cell separation system; MyD88, myeloid differentiation primary
response gene 88; NF-κB, nuclear factor kappa-light-chain-enhancer of activated
B cells; PA, perillyl alcohol; STBM, syncytiotrophoblast membrane microparticles;
STBM-NP, STBM derived from normal placentas; STBM-PE, STBM derived from
preeclamptic placentas; TLR, toll-like receptor.
systemic inflammatory response toward term, however in a much
milder form as found in preeclampsia (5).
On the other hand, it is well-acknowledged that the pla-
centa plays a crucial role in the development of the systemic
maternal symptoms of preeclampsia. Over the years, evidence
for abnormal development, function, and tissue turnover of the
placenta has accumulated (6–8). We and others have suggested
that placenta-derived syncytiotrophoblast membrane micropar-
ticles (STBM), which are shed into maternal blood in higher
amounts in preeclampsia as compared to normotensive preg-
nancies (9), may play an active role in stimulating the mother’s
inflammatory response (10–12). In vitro, STBM interfere with
human umbilical vein endothelial cell proliferation and survival
or with the relaxation of artificially pre-constricted small subcu-
taneous fat arteries (13–16). In addition, STBM induce a strong
pro-inflammatory response in donor-derived human peripheral
polymorphonuclear leukocytes (17) and in human peripheral
blood monocytes (18, 19). In monocytes, the production of the
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pro-inflammatory cytokines tumor necrosis factor (TNF) α, inter-
leukin (IL)-12, IL-6 and of the chemokine IL-8 is increased,
whereas the cells also adopt a cell surface expression pattern
with up-regulation of the adhesion molecule CD54, which is very
reminiscent of the pattern exhibited by peripheral blood mono-
cytes freshly harvested from pregnant women (20). Compared
to non-pregnant controls, circulating monocytes from healthy
pregnant women display an inflammatory phenotype, which is
hallmarked by an enhanced phagocytic activity, elevated basal
production of reactive oxygen species (21), and increased pro-
duction of pro-inflammatory mediators (22). In preeclampsia,
peripheral monocytes are more extensively activated when com-
pared to their counterparts in normal pregnancy, with a further
increase in the production of IL-1β, IL-6, and IL-8 (23). These
latter features concur with our previous results indicating that
STBM generated from normal placentas had the potential to
stimulate monocytes in a dose-dependent manner (19). There-
fore, we suggested that the progressive monocytic activation in
the maternal peripheral blood during pregnancy might be due
to the steady increase in the amount of placental microparticles
as gestational age advances. We also proposed that the exces-
sive monocytic activation in preeclampsia might be correlated
with the elevated circulatory STBM concentrations existing in
this pregnancy condition. However, evidence that microparti-
cles shed from preeclamptic placentas similarly stimulate mono-
cytes is still scarce. Interestingly, plasma-derived microparticles
from preeclamptic women activate endothelial cells in vitro, in
the presence of monocytes, to a higher extent than micropar-
ticles isolated from normotensive women (24). This study did
however not identify the specific subgroup of microparticles,
which affected the co-cultures of endothelial cells with mono-
cytes and did not detail the monocytic contribution to endothe-
lial cell activation. Therefore, in the present study, we pre-
pared STBM in vitro by explant cultures of preeclamptic pla-
centas and investigated their effect on human peripheral blood
monocytes.
MATERIALS AND METHODS
IN VITRO GENERATION OF STBM
This study was approved by the local ethical committee (Can-
tonal Institutional Review Board of Basel, Switzerland). In all
cases, written informed consent was received. Human term pla-
centas from uncomplicated pregnancies and placentas from cases
with preeclampsia were collected in the Department of Obstetrics
and Gynecology, University Hospital of Basel, within 1 h following
elective or secondary cesarean section. Explants from villous tissue
were set in culture in a controlled atmosphere (37°C, 20% oxy-
gen/5% carbon dioxide) as described previously (19). STBM were
isolated from the culture supernatants by a three-step centrifuga-
tion procedure at 4°C, namely 1000× g for 10 min, 10,000× g for
10 min, and 60,000× g for 90 min. The microparticle-containing
pellet was washed with PBS, re-suspended in PBS/5% sucrose
and stored at −20°C until use. The protein content of the
STBM was quantified with the Advanced Protein Assay Reagent
(Cytoskeleton Inc., Denver, CO, USA) and STBM were stan-
dardized for protein concentrations as indicated in the figure
legends.
ISOLATION OF HUMANMONOCYTES
Forty milliliters of venous blood from healthy male donors,
which were collected in EDTA-containing tubes, were centrifuged
on Histopaque (Sigma, Saint Louis, MO, USA) density gradient
according to the manufacturer’s instructions. Peripheral blood
mononuclear cells (PBMCs) were washed twice with PBS supple-
mented with 2 mM EDTA and the residual erythrocytes were lysed
with the red blood cell lysis solution (Qiagen, Valencia, CA, USA).
Monocytes were isolated through negative selection by means of
the Human Monocyte Isolation Kit II and a magnetic cell separa-
tion system (MACS), according to the manufacturer’s instructions
(Miltenyi Biotec Inc., Auburn, CA, USA).
CO-CULTURE OF MONOCYTES AND STBM
Monocytes were cultured in a final concentration of 5× 105
cells/ml in RPMI-1640 (Gibco, Grand Island, NY, USA) sup-
plemented with 10% FCS (Amimed, Allschwil, Switzerland),
4 mM glutamine (Gibco), and 100 U/ml penicillin/streptomycin
(Gibco). Cells were either left untreated or co-incubated with
different amounts of STBM as mentioned in the figure legends,
or stimulated with lipopolysaccharide (LPS) from Gram-negative
bacteria (Sigma) as positive control. In some experiments, mono-
cytes were pre-treated for 15 min with the phagocytosis inhibitor
cytochalasin B (Sigma), or the NF-κB inhibitors 6-amino-4-(4-
phenoxyphenylethylamino) quinazoline (Calbiochem, San Diego,
CA, USA) and perillyl alcohol (PA) (Sigma), or for 24 h with a
peptide inhibiting myeloid differentiation response gene (MyD)
88 homodimerization, before addition of STBM. Co-cultures were
incubated during 4 h (RNA analysis), 12 h (cytokine analysis after
the inhibition of MyD88 homodimerization), or 16 h (flow cytom-
etry and cytokine analysis) at 37°C in 20% oxygen/5% carbon
dioxide. At the end of the culture, the cells and the culture super-
natants were separately harvested for further analysis. Cell viability
was confirmed with the Cell Proliferation Reagent WST-1 (Roche
Diagnostics GmbH; Mannheim, Germany).
FLOW CYTOMETRY
Monocytes were first incubated with 200µg/ml of purified human
IgG (Sigma) in PBS supplemented with 2 mM EDTA and 1%
FCS for 5 min at 4°C to prevent unspecific binding through
Fc receptors. Incubations with specific antibodies were car-
ried out for 15 min at 4°C with ready-to-use concentrations
of FITC-conjugated antibodies against CD14 (BD Pharmingen,
San Jose, CA, USA) and PE-conjugated antibodies against CD54
(BD Pharmingen) or APC-conjugated antibody against CD11a
(BD Pharmingen). Labeled cells were washed with PBS and re-
suspended in PBS supplemented with 2 mM EDTA and 0.5% BSA.
The data was acquired on a Dako Cyan flow cytometer (Beck-
man Coulter, Fullerton, CA, USA) and analyzed with the Summit
software.
ENZYME-LINKED IMMUNOSORBENT ASSAY
The secreted levels of IL-8 and IL-6 were measured in duplicates
using the respective DuoSet® enzyme-linked immunosorbent
assay (ELISA) development kits (R&D Systems Inc., Minneapolis,
MN, USA), according to the manufacturer’s protocol. Plates were
read at 450 nm with a wavelength correction set at 562 nm, in the
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Spectramax 250 microplate reader (Molecular Devices, Sunnyvale,
CA, USA) and analyzed with Softmax Pro software (Molecular
Devices).
FLUORESCENT MICROSCOPY
Purified monocytes were incubated in 1µM carboxyfluorescein
succinimidyl ester (CFSE) (kindly provided by Prof. G. Spag-
noli, Department of Biomedicine, University Hospital of Basel)
in the dark at 37°C for 10 min. The staining reaction was stopped
with 2 ml of complete RPMI-1640 culture medium. Cells were
washed three times with PBS and re-suspended in complete RPMI-
1640 culture medium. STBM were diluted 1:10 in diluent C and
incubated with 5µM PKH26, using the PKH26 Red Fluorescent
Cell Linker kit (Sigma). After 5 min of incubation at RT, the
staining was stopped with 2 ml FCS (Amimed, Allschwil, Switzer-
land). STBM were washed with PBS and re-suspended in PBS/5%
sucrose. The CFSE-labeled monocytes (5× 105 cells/ml) were co-
cultured with 100µg/ml PKH26-labeled STBM for 16 h at 37°C.
Cells were then harvested, washed with PBS, and transferred by
cyto-centrifugation onto a glass slide (Shandon, Frankfurt, Ger-
many). Slides were dried at RT in the dark, fixed with 4% formalde-
hyde (Sigma) for 30 s, counterstained with 0.01% DAPI/Glycerol
(Fluka Chemie GmbH, Buchs, Switzerland), and immediately
examined with an Axioplan 2 imaging fluorescent microscope
using the appropriate filters (Carl Zeiss, Zürich, Switzerland).
RNA EXTRACTION AND REVERSE TRANSCRIPTION
Monocytes were washed with ice-cold PBS and lysed in 500µl Tri-
zol reagent (Gibco). After centrifugation at 12,000× g at 4°C, the
aqueous phase was collected and 0.5 volume of ice-cold EtOH was
added. RNA was then isolated using the RNAeasy Mini kit (Qia-
gen, Valencia, CA, USA) according to the manufacturer’s protocol.
The concentration of RNA was determined by spectrophotometry
(NanoDrop Technologies, Wilmington, DE, USA). One hundred
sixty seven nanograms of RNA were reverse-transcribed using
500 ng random primers included in the Reverse Transcription Sys-
tem (Promega Corporation, Madison, WI, USA). The reaction was
performed on a TRIO-Thermoblock (Biometra, Goettingen, Ger-
many) under the following conditions: 10 min at 37°C, 60 min at
45°C, 5 min at 95°C, and 15 min at 4°C.
REAL-TIME PCR
The human NF-κB signaling pathway RT2 profiler PCR array is a
commercially available real-time PCR based assay (SABiosciences,
Frederick, MD, USA), which profiles the expression of 84 key
genes involved in the NF-κB signaling transduction. The plates
were received pre-coated with forward and reverse primers of the
respective genes. For one 96-well plate, 102µl of cDNA was mixed
with 1275µl of 2× SuperArray RT2 qPCR master mix and filled up
with H2O to the final volume of 2550µl. Twenty-five microliters
of the experimental cocktail were pipetted into each well of the
PCR array. The PCR was run with the following PCR cycling pro-
gram on ABI PRISM® 7000 Sequence Detection System (Applied
Biosystems Inc., Forster City, CA, USA): 10 min at 95°C, followed
by 40 cycles of 15 s at 95°C and 1 min at 60°C. The data were ana-
lyzed with the delta–delta C t method using the online software
provided on the company’s webpage and expressed as fold change
(2−∆∆Ct ) relative to the untreated cells.
STATISTICAL ANALYSIS
To calculate the significance of differences between the experi-
mental groups, the Mann–Whitney test was performed using SPSS
15.0 (Statistical Package for the Social Sciences; Chicago, IL, USA).
p< 0.05 was considered to be statistically significant.
RESULTS
STBM GENERATED BY EXPLANT CULTURES OF PREECLAMPTIC
PLACENTAS ACTIVATE HUMAN PERIPHERAL BLOOD MONOCYTES IN A
SIMILAR WAY AS STBM DERIVED FROM NORMAL PLACENTAS
(STBM-NP)
Since only a minor fraction of all microparticles circulating in
the blood of healthy pregnant women are shed from the placenta
(25), STBM are usually generated in vitro. Recently, we established
short-term explant cultures of villous tissue to produce STBM-
NP (14). Here, this method was applied on placentas, which were
collected from women with preeclampsia.
To investigate if the microparticles generated from the
preeclamptic placentas (STBM-PE) altered the expression pro-
file of the inflammatory markers CD54 and CD11a on pri-
mary human monocytes, the cells were incubated with STBM-
PE for 16 h and cell surface expression was monitored by flow
cytometry. More than 95% of the cells expressed the monocyte-
specific marker CD14 and its expression remained unchanged
with incubation with the microparticles (Figure S1 in Supplemen-
tary Material). On the contrary, the expression levels of CD54
were significantly increased [mean increase of median fluores-
cence intensity (MFI)± SEM: 641.2± 122.5, p< 0.01] and the
levels of CD11a were significantly decreased (mean decrease of
MFI± SEM: 583.4± 77.2, p< 0.01) following co-culture with
STBM-PE (Figure 1). This was very comparable to the changes
triggered by STBM-NP, except for CD11a, which was only
modestly affected by the latter (Figure 1B, lower panels).
In our previous study, we showed that STBM-NP stimulated
primary monocytes to secrete soluble mediators of inflammation
(19). Therefore, the effect of STBM-PE on the monocytic produc-
tion of the pro-inflammatory cytokine IL-6 and the chemokine
IL-8 was investigated. This analysis showed that STBM-PE stimu-
lated the secretion of IL-6 and IL-8 in a dose-dependent manner,
as did STBM-NP. Furthermore, both microparticle populations
induced similar concentrations of cytokines at identical doses
(Figure 2). However, a higher sample number would be required
to test for the absence of a difference.
MONOCYTIC ACTIVATION DOES NOT REQUIRE PHAGOCYTOSIS OF THE
STBM
As both populations of STBM triggered similar inflammatory
responses in primary monocytes, the molecular mechanisms of
cell activation were addressed using the more available STBM-
NP. To assess whether placental microparticles could interact with
human monocytes, they were labeled with the red fluorescent
lipophilic dye PKH26 prior incubation with the cells. Flow cyto-
metric analysis revealed that all monocytes became highly positive
for PKH26, which indicates that STBM directly interact with the
cells (Figure 3A). However, this analysis did not permit to local-
ize precisely the microparticles. Therefore, the experiment was
repeated with monocytes pre-treated with the green fluorescent
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FIGURE 1 | STBM from normal and preeclamptic placentas alter the
cell surface expression of CD54 and CD11a on monocytes. Primary
human monocytes were left untreated or were co-cultured with 300µg/ml
STBM prepared from normal (STBM-NP) or preeclamptic (STBM-PE)
placentas for 16 h. The cell surface expression of CD54 and CD11a was
evaluated on CD14-positive cells using flow cytometry. (A) Representative
forward/side scatter dot plots of untreated or STBM-treated cells.
(B) Representative histograms of CD54 or CD11a expression on untreated
or STBM-treated monocytes. The co-culture experiments were performed
two times with five different STBM-NP preparations and three independent
STBM-PE preparations.
intracellular dye CFSE and PKH26-labeled STBM-NP and ana-
lyzed by fluorescence microscopy. STBM were regularly found on
the rim of the cells, suggesting that they bind to but are not inter-
nalized by the cells (Figure 3B). In some cases, clamps of STBM
formed and attached on the cell surface (Figure 3B, lower panel).
To verify that internalization of the placental microparticles
was not required to activate the cells, the monocytes were pre-
treated with cytochalasin B, a cell-permeable mycotoxin that
blocks phagocytosis, prior addition of the microparticles. Nei-
ther cytochalasin B nor the drug-carrier DMSO interfered with
the STBM-induced secretion of IL-8 and IL-6 (Figure 3C). Cell
viability after culture was confirmed (Figure S2 in Supplementary
Material).
TOLL-LIKE RECEPTORS ARE INVOLVED IN THE STBM-INDUCED
ACTIVATION OF MONOCYTES
As STBM interact with the cell surface of monocytes, we checked
whether cell membrane receptors of the toll-like family (TLR)
FIGURE 2 | STBM produced from normal and preeclamptic placentas
induce a similar dose-dependent pro-inflammatory response in
monocytes. Primary monocytes were incubated with increasing
concentrations of STBM prepared from normal (STBM-NP) or preeclamptic
(STBM-PE) placentas for 16 h. The cellular secretion of IL-8 (A) and IL-6
(B) was measured by conventional ELISA. Results are illustrated as
mean±SEM of two independent monocyte co-culture experiments with
five STBM-NP preparations and three STBM-PE preparations. There is no
statistical difference between the responses generated by the two different
STBM populations.
may be involved. Accordingly, monocytes were pre-treated with
a peptide inhibiting MyD88 homodimerization, a broad TLR
blocking agent,prior incubation with LPS or STBM-NP. LPS trans-
mits intracellular activation signals through TLR4. Pre-treatment
of monocytes with MyD88 inhibitory peptide partially impaired
LPS-induced secretion of IL-6 and IL-8 (Figure 4). In a similar way,
incubation of monocytes with STBM-NP in the presence of the
MyD88 inhibitory peptide lead to significantly reduced secretion
of both pro-inflammatory mediators compared to cells cultured
with STBM-NP alone (Figure 4). Thus, placental microparticles
appear to activate monocytes, at least in part, via one or several
members of the TLR family.
STBM ACTIVATE MONOCYTES IN AN NF-κB-DEPENDENT MANNER
In order to establish whether the secretion of IL-6 and IL-8 in
response to STBM stimulation was due to de novo gene transcrip-
tion, we analyzed mRNA levels by relative real-time PCR. IL-6
and IL-8 mRNA levels were increased 120-fold and 4-fold, respec-
tively, upon STBM-treatment compared to untreated monocytes
(Figure 5A). The transcription of several other mediators involved
in the inflammatory response, such as IL-1α, IL-1β, IL-10, lympho-
toxin (LT)-α, and the TNF, was also induced (Figure 5A). Besides
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FIGURE 3 | STBM interact with monocytes, but phagocytosis is not
required for their stimulatory properties. PKH-26-labeled STBM-NP
(300µg/ml) were incubated with monocytes for 16 h and analyzed by flow
cytometry or fluorescence microscopy. (A) Representative histograms of
CD14-positive monocytes read in the FL1 (CD14) and FL2 (PKH-26)
channels. (B) Fluorescence microscopy of CSFE-stained monocytes (green)
incubated with PKH-labeled STBM (red). DAPI (blue) was used as a nuclear
counterstain. (C) Monocytes were pre-treated with various concentrations
of cytochalasin B in DMSO or with DMSO alone, prior to the addition of
300µg/ml STBM. The levels of IL-8 and IL-6 secreted by the cells after 16 h
of incubation are expressed as a percentage of the amounts produced by
cells stimulated with STBM in the absence of the inhibitor, which was set
at 100%. Data represent mean±SEM of three different co-cultures with
STBM-NP prepared from three placentas. There was no statistical
difference between cytokine secretion in the absence or in the presence of
cytochalasin B.
stimulating the transcription of several targets, STBM-NP also
down-regulated the transcription of molecules involved in apop-
tosis, like caspase-8 (2−∆∆Ct = 0.32), CD27 (2−∆∆Ct = 0.43),
and Fas-associated protein with death domain (FADD; 2−∆∆Ct =
0.5) (data not shown).
The gene transcription of these pro-inflammatory mediators
is controlled in large part by nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) (26). Hence, the potential
participation of NF-κB in the activated phenotype of STBM-
treated monocytes was confirmed using 6AQ and PA, two dis-
tinct inhibitors of NF-κB activation. Both inhibitors significantly
decreased IL-6 and IL-8 secretion induced by STBM-NP compared
FIGURE 4 | Inhibition of MyD88 homodimerization reduces
STBM-induced pro-inflammatory response. Primary monocytes were
pre-treated with 1µM MyD88 inhibitor peptide for 24 h prior incubation
with the indicated concentrations of LPS or STBM-NP during 12 h. The
concentrations of IL-8 (A) and IL-6 (B) secreted by the cells were quantified
by ELISA and are presented as a percentage of the amounts secreted in
absence of pre-treatment with the inhibitor. Data represent mean±SEM of
three monocyte co-culture experiments with STBM-NP prepared from four
placentas. *p<0.05; **p<0.01. LPS was used as a positive control.
to cells co-cultured with the microparticles in the absence of the
inhibitors (Figure 5B). DMSO, which was used as a carrier for
6AQ, had no effect on IL-6 or IL-8 release. In all instances, cell via-
bility following treatment with the drugs was confirmed (Figure
S2 in Supplementary Material). As positive control, LPS, which
activates NF-κB function, was used to stimulate monocytes. The
LPS-induced release of IL-6 was also partially reduced by the same
concentrations of either NF-κB inhibitors (Figure 5C).
DISCUSSION
Syncytiotrophoblast microparticles have been attributed poten-
tial roles in the systemic maternal inflammatory response during
normal pregnancy and in the enhanced inflammatory reaction
in preeclampsia (18, 19). In contrast to syncytial knots and
larger placental debris, eliciting a local inflammatory response
upon phagocytosis by endometrial endothelial cells (27), and
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FIGURE 5 |The effect of STBM on monocytes is partly mediated by
NF-κB. (A) Monocytes were incubated during 4 h without or with
300µg/ml STBM-NP prepared from three different placentas. Cellular
RNA was extracted, reverse-transcribed, and the pooled cDNA was
examined for the expression of several genes. Transcript fold change
was calculated with the 2−∆∆Ct . (B,C) Monocytes were pre-incubated
with either 10µM 6AQ, or 10µM PA or DMSO alone prior to addition of
(B) 300µg/ml STBM-NP or (C) 100 pg/ml LPS. After 16 h of incubation,
cytokine secretion was measured by ELISA and reported as a
percentage of secretion relative to that of monocytes stimulated by
STBM-NP in the absence of any drug. Data are presented as
mean±SEM of three independent co-culture experiments with four
STBM-NP preparations. *p<0.05; **p<0.01. LPS was used as a
positive control.
which are trapped by alveolar macrophages in the lungs (28,
29), STBM reach the maternal peripheral circulation, where they
may come into contact with maternal endothelial and immune
cells. Here, we showed that STBM derived from placentas col-
lected from women with diagnosed preeclampsia or from women
with uneventful pregnancy had a comparable effect on mono-
cytes. STBM-PE, like STBM-NP, increased the cell surface levels
of CD54 and induced the secretion of pro-inflammatory factors
on monocytes. The cellular response to either STBM population
was dose-dependent and equally strong at equivalent concentra-
tions of microparticles. Our data would therefore indicate that the
exaggerated inflammatory reaction in patients with preeclampsia
may be attributed to the elevated levels of circulating placental
microparticles rather than to a differential nature of the parti-
cles in preeclampsia compared to normal pregnancy. However,
it needs to be mentioned that STBM-PE significantly altered the
cellular expression of CD11a, whereas STBM-NP had no effect
on this adhesion molecule. Hence, this could indicate that the
adhesion properties of the monocytes may change differently
upon their interaction with STBM in preeclamptic patients com-
pared to normotensive pregnant women. Others have shown
that microvesicles produced from preeclamptic placentas in vitro
had an exacerbated pro-inflammatory effect on PBMCs when
compared to normal term microvesicles (30), giving a hint that
the placental debris shed by preeclamptic placentas may pos-
sibly be qualitatively different from the placental micro-debris
circulating in the blood of normotensive women. Alluding to
this hypothesis, a recent study demonstrated that microparticles
derived from a trophoblast cell line cultured under hypoxia, as
a model for the preeclamptic placenta, triggered a more rapid
inflammatory response in PBMC than the particulate material
derived from the cell line cultured under normal oxygen condi-
tions (31). It was also recently shown that the monocytic frac-
tion of PBMC was at the origin of the production of IL-6 and
IL-8 upon stimulation with STBM obtained through placen-
tal perfusion (32). Whether this effect was direct or mediated
by the other immune cells present in PBMC was however not
determined.
Here, we observed that STBM localized at the boundary of
monocytes, suggesting that the microparticles interact with these
cells via one or several cell surface molecules. These results are
in line with a former study, which documented the physiologic
binding of placental microparticles onto circulating monocytes in
peripheral blood of normal pregnant women and patients with
preeclampsia (18). Similarly, STBM collected from placental per-
fusion were shown to bind and to be internalized by monocytes
in vitro (32).Furthermore,we provide evidence against the require-
ment for STBM internalization by showing that the phagocytosis
inhibitor cytochalasin B did not affect the secretion of IL-6 and
IL-8 in response to the microparticles.
Therefore, the activation of monocytes involves receptors
encompassed on the cellular membrane. In this respect, TLRs
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might be potential candidates, as they mediate inflammatory
responses in a number of immune cells following stimulation
by a large panel of triggers, including host-derived molecules
(33). TLRs transduce activation signals through the adaptor pro-
tein MyD88 (34). MyD88 is bound to the intracellular domain
of the TLRs and, upon receptor stimulation, it homodimerizes
and recruits IL-1 receptor-associated kinase, leading to the acti-
vation of the transcription factors NF-κB and JNK. We show
here that MyD88 homodimerization inhibitory peptide partially
blocks the secretion of IL-6 and IL-8, which strongly suggests that
one or several members of the TLR family might be involved
in the STBM-induced activation of monocytes. Downstream of
TLRs, NF-κB is a well-known master switch in intracellular sig-
naling pathways, which regulates the expression of numerous
pro-inflammatory genes required to mount a cellular response
in immune cells (26). In monocytes, the mRNA levels of a number
of NF-κB responsive genes, including IL-6, IL-8, IL-1, LT-α, and
TNF, were up-regulated following STBM treatment. The change
in mRNA expression was even higher than 100 fold for IL-6. On
the contrary, the levels of IL-8 transcripts were only marginally
enhanced despite the large amounts of IL-8 that was secreted
by the cells. This observation could point to the presence of
an intracellular reservoir of pre-stored IL-8 in monocytes, as it
is the case in Weibel–Palade bodies in microvascular endothe-
lial cells (35). What may at first hand appear more intriguing is
that STBM also induced the expression of the gene coding for
the anti-inflammatory cytokine IL-10. This could be part of a
negative feedback mechanism to maintain homeostatic control
and terminate the inflammatory reaction (36). We also found
that STBM decreased transcript levels of the pro-apoptotic mol-
ecules FADD, caspase-8, and CD27, which is in agreement with
the role of NF-κB in promoting cell survival (37). Both inhibitors
of NF-κB function, 6AQ and PA, independently affected cytokine
secretion induced by STBM. 6AQ is a cell-permeable quinazoline
compound, which inhibits NF-κB transcriptional activation (38),
whereas PA is thought to block the calcium-dependent NF-κB
signaling (39). It is known that these inhibitors can induce cellu-
lar apoptosis, since NF-κB also functions as a cell survival factor.
However, the reduced production of IL-6 and IL-8 in the pres-
ence of 6AQ or PA was not due to cell death as the viability of
the monocytes at the end of the co-culture with the microparticles
was confirmed.
Activation of the NF-κB signaling pathway in PBMCs of
preeclamptic women remains controversial. On the one hand, an
increased activation of NF-κB in PBMC of preeclamptic patients
compared to normal pregnant controls was reported (40). On
the other hand, evidence for a suppression of the NF-κB activa-
tion pathway in preeclampsia was also provided elsewhere (41).
However, this suppression might be attributed to the T-cell subset
rather than to the monocytes (42).
In conclusion, the current analysis suggests that even though
there may be minor qualitative differences between placental
microparticles derived from normal or preeclamptic placen-
tas, both can stimulate primary monocytes to produce pro-
inflammatory cytokines. This effect appears to be mediated at
least in part through TLR and NF-κB, leading to de novo gene
transcription. Recent compelling investigations have led to the
speculation that the size of the placental particulate debris cir-
culating in the maternal blood may also have its importance in
preeclampsia (43, 44). Therefore, further investigation will be
required to identify the subgroup of placental microparticles and
their components, which transmit pro-inflammatory signals to the
maternal immune cells in order to complete our understanding of
the inflammatory reactions taking place in both normal pregnancy
and preeclampsia.
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